Nuvectis Pharma, Inc. announced a collaboration with the European Network of Gynecological Oncology Trial Groups (ôENGOTö) and the GOG Foundation, Inc. (ôGOG-Fö) to conduct the NXP800 Phase 1b clinical trial in ARID1A-mutated, ovarian clear cell and endometroid carcinomas in Europe and the United States. ENGOT is a research network of the European Society of Gynecological Oncology (ESGO) and was founded in Berlin in October 2007. Currently, ENGOT consists of 21 trial groups from several European countries that perform cooperative clinical trials.

The ultimate goal of ENGOT is to bring the best treatment to gynecological cancer patients through the best science, and enabling every patient in every European country to access a clinical trial. The ENGOT reference number for the Phase 1b clinical trial of NXP800 is ENGOT-GYN5/NCRI/NXP800-101.